Itochu, US Bio Venture Peptimmune to Form Capital and Business Alliance.Tokyo, Japan, Nov 2, 2005 - (JCNN JCNN Japan Corporate News Network ) - Itochu has invested $1 million in Peptimmune, Inc., a US venture company specializing in the field of metabolic and autoimmune diseases Autoimmune diseases A group of diseases, like rheumatoid arthritis and systemic lupus erythematosus, in which immune cells turn on the body, attacking various tissues and organs. Mentioned in: Complement Deficiencies, Premature Menopause . In addition, the two companies have entered into a business alliance, by which Itochu will support Peptimmune's business deployment in Japan. Peptimmune's lead investor is MPM MPM Multi-Processing Module (Apache) MPM Manufacturing Process Management MPM Milwaukee Public Museum MPM MMW (Millimeter Wave) Power Module MPM Master of Project Management (degree) Capital (MPM), Itochu's strategic partner and the world's leading bio venture capital group located in the US. Accordingly, Itochu and MPM will jointly support Peptimmune's anagement with a view to launching an initial public offering at the earliest date possible. Through these means, Itochu aims to strengthen its earnings base in the biotechnology business. Source: JCN JCN Japan Corporate News JCN Journal of Cognitive Neuroscience JCN Journal of Cardiovascular Nursing JCN Journal of Christian Nursing JCN Job Control Number JCN Journal of Child Neurology JCN joint communications network (US DoD) http://www.japancorp.net Copyright [c] 2005 Japan Corporate News Network. All rights reserved. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion